Oral Treosulfan as Second-Line Treatment in Platinum-Resistant Ovarian Cancer: A Phase II Study
Authors:
- Ebbe Lindegaard MadsenEMEbbe Lindegaard Madsen
- Hanne HavsteenHHHanne Havsteen
- Claus KambyCKClaus Kamby
- Lone LaursenLLLone Laursen
- Erik SandbergESErik Sandberg
- 1 May 1998
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 69 (2) , 100-102
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.Journal of Clinical Oncology, 1996
- A Phase 2 Study with Epirubicin as Second-Line Treatment of Patients with Advanced Epithelial Ovarian CancerGynecologic Oncology, 1996
- Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The EORTC Core Quality of Life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapyEuropean Journal of Cancer, 1995
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.Journal of Clinical Oncology, 1992
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991